2026 Global: Coagulation Factor Concentrates Market -Competitive Review (2032) report
Description
The 2026 Global: Coagulation Factor Concentrates Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Grifols S.A., based in Barcelona, Spain, is a leading manufacturer of plasma-derived coagulation factor concentrates used to treat hemophilia and other bleeding disorders. The company’s portfolio includes Factor VIII and IX products, along with prophylactic and therapeutic plasma-derived therapies, positioning Grifols as a major global supplier. CSL Behring, headquartered in King of Prussia, United States, is another dominant player with a broad range of coagulation products, including Factor VIII and IX concentrates and bypassing agents. Takeda Pharmaceutical Company Limited, headquartered in Tokyo, Japan, has expanded its coagulation portfolio through legacy Shire assets and internal development, offering recombinant and plasma-derived options for bleeding disorders. Bayer AG, based in Leverkusen, Germany, remains a significant force with recombinant and plasma-derived Factor VIII products and related coagulation therapies. These firms maintain manufacturing footprints and global distribution to hospitals. Their portfolios evolve with extended half-life products and inhibitors management strategies, adapting to clinical settings today.
Novo Nordisk A/S, headquartered in Bagsværd, Denmark, is a global leader in coagulation therapies, with a focus on recombinant and extended half-life Factor VIII and VIIa products. Octapharma AG, based in Lachen, Switzerland, operates a broad coagulation portfolio including Factor VIII and von Willebrand factor concentrates, supported by international manufacturing facilities. Kedrion Biopharma, Castel San Pietro Terme, Italy, provides plasma-derived and recombinant coagulation products to markets worldwide, emphasizing affordability and patient access across regions, with continued expansion. Swedish Orphan Biovitrum AB, known as Sobi, is headquartered in Stockholm, Sweden, and markets recombinant Factor IX therapies as well as Factor VIII and novel hemostatic agents. These four companies together shape procurement, pricing, and innovation strategies across worldwide hemophilia care networks, while expanding access through partnerships, patient support programs, and regional manufacturing expansions. Continued investment in recombinant technology and plasma fractionation capabilities reinforces resilience against supply disruptions. This market remains strategically vital.
Shire plc, headquartered in Dublin, Ireland, has a diversified coagulation portfolio including recombinant Factor VIII and IX therapies, together with infrastructure to support urgent care and specialized bleeding management worldwide. Biotest AG, based in Dreieich, Germany, produces coagulation factor concentrates such as Factor IX–based products and PCCs, with a focus on surgical hemostasis and trauma care. Post acquisitions, Shire’s portfolio integrated with Takeda operations, expanding the global footprint and distribution networks that serve patients across multiple continents. Biotest maintains manufacturing sites in Germany and Austria, enabling rapid supply to European markets and a growing presence in other regions. Together, these producers drive ongoing innovation, address pricing and access challenges, and support patient education initiatives. Global supply resilience, regulatory alignment, and strategic collaborations will shape the next decade of care for bleeding disorders. This market remains strategically vital. Continued R&D investments sustain progress toward safer, more accessible therapies worldwide for patients.
Grifols S.A., based in Barcelona, Spain, is a leading manufacturer of plasma-derived coagulation factor concentrates used to treat hemophilia and other bleeding disorders. The company’s portfolio includes Factor VIII and IX products, along with prophylactic and therapeutic plasma-derived therapies, positioning Grifols as a major global supplier. CSL Behring, headquartered in King of Prussia, United States, is another dominant player with a broad range of coagulation products, including Factor VIII and IX concentrates and bypassing agents. Takeda Pharmaceutical Company Limited, headquartered in Tokyo, Japan, has expanded its coagulation portfolio through legacy Shire assets and internal development, offering recombinant and plasma-derived options for bleeding disorders. Bayer AG, based in Leverkusen, Germany, remains a significant force with recombinant and plasma-derived Factor VIII products and related coagulation therapies. These firms maintain manufacturing footprints and global distribution to hospitals. Their portfolios evolve with extended half-life products and inhibitors management strategies, adapting to clinical settings today.
Novo Nordisk A/S, headquartered in Bagsværd, Denmark, is a global leader in coagulation therapies, with a focus on recombinant and extended half-life Factor VIII and VIIa products. Octapharma AG, based in Lachen, Switzerland, operates a broad coagulation portfolio including Factor VIII and von Willebrand factor concentrates, supported by international manufacturing facilities. Kedrion Biopharma, Castel San Pietro Terme, Italy, provides plasma-derived and recombinant coagulation products to markets worldwide, emphasizing affordability and patient access across regions, with continued expansion. Swedish Orphan Biovitrum AB, known as Sobi, is headquartered in Stockholm, Sweden, and markets recombinant Factor IX therapies as well as Factor VIII and novel hemostatic agents. These four companies together shape procurement, pricing, and innovation strategies across worldwide hemophilia care networks, while expanding access through partnerships, patient support programs, and regional manufacturing expansions. Continued investment in recombinant technology and plasma fractionation capabilities reinforces resilience against supply disruptions. This market remains strategically vital.
Shire plc, headquartered in Dublin, Ireland, has a diversified coagulation portfolio including recombinant Factor VIII and IX therapies, together with infrastructure to support urgent care and specialized bleeding management worldwide. Biotest AG, based in Dreieich, Germany, produces coagulation factor concentrates such as Factor IX–based products and PCCs, with a focus on surgical hemostasis and trauma care. Post acquisitions, Shire’s portfolio integrated with Takeda operations, expanding the global footprint and distribution networks that serve patients across multiple continents. Biotest maintains manufacturing sites in Germany and Austria, enabling rapid supply to European markets and a growing presence in other regions. Together, these producers drive ongoing innovation, address pricing and access challenges, and support patient education initiatives. Global supply resilience, regulatory alignment, and strategic collaborations will shape the next decade of care for bleeding disorders. This market remains strategically vital. Continued R&D investments sustain progress toward safer, more accessible therapies worldwide for patients.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
